Table 1.
Correlation between CXCL12 expression in cancer-associated fibroblast, tumoral Wnt5a and clinicopathological variables in 285 gastric cancer patients
| Clinical parameters | CXCL12CAF | P value | Wnt5a | P value | ||
|---|---|---|---|---|---|---|
| Positive (N=136) | Negative (N=149) | Positive (N=124) | Negative (N=161) | |||
| Gender | 0.903 | 0.231 | ||||
| Male | 74 (54.4%) | 80 (53.7%) | 72 (58.1%) | 82 (50.9%) | ||
| Female | 62 (45.6%) | 69 (46.3%) | 52 (41.9%) | 79 (49.1%) | ||
| Age | 0.456 | 0.238 | ||||
| <60 | 57 (41.9%) | 56 (37.6%) | 54 (43.5%) | 59 (36.6%) | ||
| ≥60 | 79 (58.1%) | 93 (62.4%) | 70 (56.5%) | 102(63.4%) | ||
| Tumor size | 0.495 | 0.343 | ||||
| <3 cm | 53 (39.0%) | 64 (43.0%) | 47 (37.9%) | 70 (43.5%) | ||
| ≥3 cm | 83 (61.0%) | 85 (57.0%) | 77 (62.1%) | 91 (56.5%) | ||
| Histological grade | 0.012* | 0.242 | ||||
| Well/moderately | 51 (37.5%) | 78 (52.3%) | 61 (49.2%) | 68 (42.2%) | ||
| Poorly | 85 (62.5%) | 71 (47.7%) | 63 (50.8%) | 93 (57.8%) | ||
| Primary tumor category (T) | 0.286 | 0.016* | ||||
| T1/T2 | 67 (49.3%) | 64 (43.0%) | 67 (54.0%) | 64 (39.8%) | ||
| T3/T4 | 69 (50.7%) | 85 (57.0%) | 57 (46.0%) | 97 (60.2%) | ||
| Lauren type | 0.204 | 0.776 | ||||
| Intestinal | 94 (69.1%) | 113(75.8%) | 89 (71.8%) | 118(73.3%) | ||
| Diffuse/Mix | 42 (30.9%) | 36 (24.2%) | 35 (28.2%) | 43 (26.7%) | ||
| TNM stage | 0.014* | 0.147 | ||||
| I II | 107 (78.7%) | 133(89.3%) | 100(80.6%) | 140(87.0%) | ||
| III IV | 29 (21.3%) | 16 (10.7%) | 24 (19.4%) | 21 (13.0%) | ||
Note: Values are n (%). *Significantly different by the Chi-squared test or Fisher exact probability method.